Axitan appoints ex Novus MD as its VP of sales & marketing
Gonzalo Prat joins fast-growing feed additive biotech firm
6 September 2024
2 minute read
By: 
Axitan Limited, a leading biotech company focused on the development of endolysin enzyme products to replace antibiotics in animal feed, is pleased to announce the appointment of Gonzalo Prat as Axitan’s Vice President of Sales & Marketing. Gonzalo will be responsible for developing the global market for the company’s growing portfolio of endolysin based products. He will be based in Chesterfield, MO, USA.
Alfred Zimmerman, CEO of Axitan, said: “Gonzalo brings an exceptional track record in driving revenue growth for innovative feed additive products in the Americas across all the main livestock categories - poultry, swine and ruminants. He joins us at a time when we are experiencing transformative growth with commercial sales having now begun for our first product for the poultry market, FORC3®. Gonzalo’s knowledge and experience will allow us both to cement and build on our current momentum.”
Gonzalo Prat was previously with Novus International for 18 years which culminated in his being appointed Senior Managing Director, Americas. In this role he successfully led and implemented the company’s new Go-to Market strategy for its speciality business unit covering enzymes, eubiotics, minerals and methionine in North and South America. Throughout his Novus career, Gonzalo consistently delivered outstanding commercial outcomes for the company and its customers.
Gonzalo Prat, Axitan VP Sales & Marketing, commented: “Axitan is at the forefront of using endolysin based technology as the mechanism of choice for safely reducing and removing antibiotics from animal feed without compromising productivity. I am deeply honoured to be joining Axitan’s experienced management team at a time when livestock producers are increasingly looking to incorporate new technologies that will help them to continue feeding the world’s expanding population in a sustainable and economically positive way.”
Since its formation, Axitan’s biotech team has pioneered the development and incorporation of endolysins into animal feed for targeting and eliminating pathogens historically managed through antibiotics. Its endolysins are formulated into nutrient rich feed additives that help provide material performance benefits to livestock farmers in addition to pathogen mitigation. Its first product in commercial production is FORC3® which specifically targets Clostridium perfringens in poultry. It also has a robust pipeline of new endolysin based products for targeting other pathogens that present production and/or food borne illness issues to the industry.
